Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 13Neoplasms 6Neoplasm Metastasis 4Thoracic Neoplasms 2Noonan Syndrome 2NSCLC 2Meningeal Carcinomatosis 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1T790M Positive NSCLC Patients 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Renal Insufficiency 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Lung Diseases 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × T790M Positive NSCLC Patients × osimertinib × Clear all
NCT03133234 2018-11-20

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

AstraZeneca

Completed
47 enrolled
Thoracic

T790M Positive NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡